- Home
- AMS vs LGVN Comparison
AMS vs LGVN Comparison
Compare AMS & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMS | LGVN |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 11.9M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AMS | LGVN |
|---|---|---|
| Price | $1.82 | $0.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 3.8K | ★ 8.9M |
| Earning Date | 05-14-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 230.00 | 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,714,000.00 | $709,000.00 |
| Revenue This Year | $3.81 | N/A |
| Revenue Next Year | N/A | $1,183.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.81 | N/A |
| 52 Week Low | $1.79 | $0.48 |
| 52 Week High | $3.11 | $1.83 |
Technical Indicators
Market Signals| Indicator | AMS | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 23.83 | 54.92 |
| Support Level | N/A | $0.55 |
| Resistance Level | $2.19 | $0.93 |
| Average True Range (ATR) | 0.05 | 0.14 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 7.35 | 33.66 |
Price Performance
Historical ComparisonAbout AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.